About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.

Influence of Hyperbilirubinaemia on Two Different Near Infrared Spectroscopy Devices

Clinicaltrials.gov identifier NCT03945942

Recruitment Status Recruiting

First Posted May 10, 2019

Last update posted May 10, 2019

Study Description

Brief summary:

Protocol Near infrared spectroscopy liver transplants: comparison of two monitoring of Near infrared spectroscopy in pediatric liver transplant.

  • Condition or Disease:Liver Transplant; Complications
  • Intervention/Treatment: Device: Near infrared spectroscopy with INVOS device
    Device: Near infrared spectroscopy with Foresight device
  • Phase: N/A
Detailed Description

Hyperbilirubinaemia may interfere with oximetry values as measured by Near Infrared Spectroscopy devices. The number of wave lengths used by different devices can influence the oximetry values in adult patients. This has never been demonstrated in children with hyperbilirubinaemia scheduled for elective liver transplantation.The study will compare cerebral and somatic oximetry values measured by two different Near infrared spectroscopy devices (FORESIGHT and INVOS) and analyse the influence of bilirubin levels on these differences.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 25 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Other
  • Official Title: Influence of Hyperbilirubinaemia on Foresight and INVOS Oximetry Values in Pediatric Hepatic Transplantation
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: March 2020
  • Estimated Study Completion Date: April 2020
Arms and interventions
Arm Intervention/treatment
Other: Pediatric liver transplant patients
Using somatic and cerebral Near infrared spectroscopy devices
Device: Near infrared spectroscopy with INVOS device
somatic and cerebral oximetry by INVOS in pediatric liver transplantation

Device: Near infrared spectroscopy with Foresight device
somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
Outcome Measures
  • Primary Outcome Measures: 1. influence of chromophores such as bilirubin on oximetry values provided by two different devices [ Time Frame: From Day 0 of surgery until arrival at pediatric intensive care unit (up to 12 hours) ]
    measure of oximetry values by two different devices at different time points in function of serum bilirubin levels
Eligibility Criteria
  • Ages Eligible for Study: up to 18 / (18 to 64 years)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Pediatric patients 0 to 18 years, with a liver transplant with living donor program of
our institution

- Free, informed and written consent signed by the investigator or employees and by the
legal guardians of minor patients in the days preceding the procedure

Exclusion Criteria:

- refusal of the patient or his parents to consent

- known brain or Neurological pathology

Contacts and Locations
Contacts

Contact: MAGASICH-AIROLA Natalia, MD +3227648034 natalia.magasich@uclouvain.be

Locations

Belgium
Cliniques Universitaires Saint-Luc
Brussels

Sponsors and Collaborators

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Investigators

Principal Investigator: Natalia MAGASICH-AIROLA, MD natalia.magasich@uclouvain.be

More Information
  • Responsible Party: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
  • ClinicalTrials.gov Identifier: NCT03945942 History of Changes
  • Other Study ID Numbers: 2018/07NOV/413
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: May 10, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Hyperbilirubinemia